Chang-Jin Lee
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Chang-Jin Lee has a total of 15 co-authors. Here are the top co-authors by number of shared publications:
- Ji Hyeon Ju
Division of Rheumatology, Department of Internal Medicine, Seoul St. Mary's Hospital, College of Medicine, The Catholic University of Korea, Seoul, Korea
3 shared publications - Yeri Alice Rim
CiSTEM laboratory, Convergent Research Consortium for Immunologic Disease, Seoul St. Mary’s Hospital, College of Medicine, The Catholic University of Korea, Seoul, Republic of Korea
3 shared publications - Dong Hee Choi
Department of Obstetrics and Gynecology, CHA Fertility Center Bundang, Gyeonggi-do, Korea
2 shared publications - Hwa Seon Koo
CHA Fertility Center Bundang, Seongnam-si, South Korea
2 shared publications - Jee Hyun Kim
Department of Obstetrics and Gynecology, CHA University
2 shared publications - Jung-Jae Ko
Department of Biomedical Science, School of Life Science, CHA University, Seongnam, Korea
2 shared publications
Latest Publications
- Open Access
- 30 July 2026
- Published by Wiley in Bioengineering & Translational Medicine
- Vol. 11 (5) , e70162
Engineering autoimmune disease models using organoids: Harnessing microenvironmental engineering for precision medicine and immunological recapitulation
Autoimmune diseases—including systemic sclerosis (SSc), systemic lupus erythematosus (SLE), and rheumatoid arthritis (RA)—are increasingly understood as programmable microenvironmental states, wherein evolving changes in matrix mechanics, barrier integrity, interferon and cytokine networks, immune‐complex deposition, and stromal–immune reciprocity progressively reshape tissue behavior. These shifting axes generate nonlinear trajectories of fibrosis, vascular injury, and joint destruction that static or reductionist in vitro systems fail to recapitulate. Organoid and organ‐on‐a‐chip platforms now allow controlled reconstruction of these dynamic microenvironments in human‐derived systems. By integrating iPSC‐derived epithelial, endothelial, stromal, and immune lineages with tunable extracellular matrix (ECM) stiffness and viscoelasticity, perfusable microvasculature, and modular innate and adaptive immune components, these systems reproduce key autoimmune phenomena. These include stiffness‐driven fibroblast activation and endothelial‐to‐mesenchymal transition (EndoMT), interferon‐conditioned barrier collapse, immune‐complex‐mediated injury, and cytokine‐dependent stromal invasion. Patient‐specific induced pluripotent stem cell (iPSC), CRISPR‐based editing of risk alleles, and controlled exposure to sera or autoantibody repertoires provide genetic and immunologic personalization, while multi‐omic profiling, spatial imaging, and machine‐learning analytics enable quantitative alignment between organoid states and patient tissues. By translating pathogenic microenvironmental logic into controllable 3D systems, these platforms establish autoimmune organoids as programmable, human‐relevant tools for mechanistic discovery, therapeutic interrogation, and precision modeling—laying the groundwork for next‐generation, potentially animal‐free pipelines and advancing personalized immunology across SSc, SLE, and RA.
- 30 July 2026
- Published by Wiley in Bioengineering & Translational Medicine
- Vol. 11 (5) , e70162
Open AccessEngineering autoimmune disease models using organoids: Harnessing microenvironmental engineering for precision medicine and immunological recapitulation
Autoimmune diseases—including systemic sclerosis (SSc), systemic lupus erythematosus (SLE), and rheumatoid arthritis (RA)—are increasingly understood as programmable microenvironmental states, wherein evolving changes in matrix mechanics, barrier integrity, interferon and cytokine networks, immune‐complex deposition, and stromal–immune reciprocity progressively reshape tissue behavior. These shifting axes generate nonlinear trajectories of fibrosis, vascular injury, and joint destruction that static or reductionist in vitro systems fail to recapitulate. Organoid and organ‐on‐a‐chip platforms now allow controlled reconstruction of these dynamic microenvironments in human‐derived systems. By integrating iPSC‐derived epithelial, endothelial, stromal, and immune lineages with tunable extracellular matrix (ECM) stiffness and viscoelasticity, perfusable microvasculature, and modular innate and adaptive immune components, these systems reproduce key autoimmune phenomena. These include stiffness‐driven fibroblast activation and endothelial‐to‐mesenchymal transition (EndoMT), interferon‐conditioned barrier collapse, immune‐complex‐mediated injury, and cytokine‐dependent stromal invasion. Patient‐specific induced pluripotent stem cell (iPSC), CRISPR‐based editing of risk alleles, and controlled exposure to sera or autoantibody repertoires provide genetic and immunologic personalization, while multi‐omic profiling, spatial imaging, and machine‐learning analytics enable quantitative alignment between organoid states and patient tissues. By translating pathogenic microenvironmental logic into controllable 3D systems, these platforms establish autoimmune organoids as programmable, human‐relevant tools for mechanistic discovery, therapeutic interrogation, and precision modeling—laying the groundwork for next‐generation, potentially animal‐free pipelines and advancing personalized immunology across SSc, SLE, and RA.
- Open Access
- 8 February 2026
- Published by Springer Nature in Stem Cell Research & Therapy
- Vol. 17 (1)
Harnessing induced pluripotent stem cells and organoids for disease modeling and precision medicine
The convergence of CRISPR genome editing, patient-derived organoids, and induced pluripotent stem cells (iPSCs) has reshaped in vitro disease modeling by enabling mechanistic investigations of human pathophysiology within genetically matched, tissue-relevant systems. Together, these technologies provide a synergistic platform for precise manipulation of disease-associated variants and support the generation of isogenic organoid models that reproduce key phenotypic and functional hallmarks across cancer, neurodegenerative, inflammatory, and monogenic disorders. In this review, we highlight how diverse CRISPR modalities—including knock-out, knock-in, CRISPRa/i, and genome-scale screening—have been applied to dissect gene function, model disease progression, and guide therapeutic development using iPSC- and organoid-based systems. We further discuss the application of these platforms in genotype- and phenotype-driven precision medicine, enabling patient stratification, drug-response prediction, and individualized treatment design. We illustrate these convergent applications with representative case studies spanning mechanistic research and early clinical translation. By combining the scalability of genome engineering with the physiological fidelity of organoids, CRISPR-integrated platforms are redefining the frontiers of experimental medicine. These approaches accelerate the discovery of disease mechanisms and actionable therapeutic targets while establishing individualized clinical strategies for complex human diseases. Collectively, they position CRISPR-enabled organoid systems as a foundational infrastructure that bridges genome editing to individualized therapy and supports next-generation precision medicine.
- 8 February 2026
- Published by Springer Nature in Stem Cell Research & Therapy
- Vol. 17 (1)
Open AccessHarnessing induced pluripotent stem cells and organoids for disease modeling and precision medicine
The convergence of CRISPR genome editing, patient-derived organoids, and induced pluripotent stem cells (iPSCs) has reshaped in vitro disease modeling by enabling mechanistic investigations of human pathophysiology within genetically matched, tissue-relevant systems. Together, these technologies provide a synergistic platform for precise manipulation of disease-associated variants and support the generation of isogenic organoid models that reproduce key phenotypic and functional hallmarks across cancer, neurodegenerative, inflammatory, and monogenic disorders. In this review, we highlight how diverse CRISPR modalities—including knock-out, knock-in, CRISPRa/i, and genome-scale screening—have been applied to dissect gene function, model disease progression, and guide therapeutic development using iPSC- and organoid-based systems. We further discuss the application of these platforms in genotype- and phenotype-driven precision medicine, enabling patient stratification, drug-response prediction, and individualized treatment design. We illustrate these convergent applications with representative case studies spanning mechanistic research and early clinical translation. By combining the scalability of genome engineering with the physiological fidelity of organoids, CRISPR-integrated platforms are redefining the frontiers of experimental medicine. These approaches accelerate the discovery of disease mechanisms and actionable therapeutic targets while establishing individualized clinical strategies for complex human diseases. Collectively, they position CRISPR-enabled organoid systems as a foundational infrastructure that bridges genome editing to individualized therapy and supports next-generation precision medicine.
- Open Access
- 11 March 2025
- Published by Korean Society for Stem Cell Research in International Journal of Stem Cells
- Vol. 18 (2) , 107-125
Advanced Animal Replacement Testing Strategies Using Stem Cell and Organoids
Chang-Jin Lee, Yoojun Nam, Yeri Alice Rim, Ji Hyeon Ju. IJSC -0001;0:. https://doi.org/10.15283/ijsc24118
- 11 March 2025
- Published by Korean Society for Stem Cell Research in International Journal of Stem Cells
- Vol. 18 (2) , 107-125
Open AccessAdvanced Animal Replacement Testing Strategies Using Stem Cell and Organoids
Chang-Jin Lee, Yoojun Nam, Yeri Alice Rim, Ji Hyeon Ju. IJSC -0001;0:. https://doi.org/10.15283/ijsc24118
- Open Access
- 1 June 2020
- Published by The Korean Society for Reproductive Medicine in Clinical and Experimental Reproductive Medicine
- Vol. 47 (2) , 114-121
Endometrial profilin 1: a key player in embryo-endometrial crosstalk
Objective: Despite extensive research on implantation failure, little is known about the molecular mechanisms underlying the crosstalk between the embryo and the maternal endometrium, which is critical for successful pregnancy. Profilin 1 (PFN1), which is expressed both in the embryo and in the endometrial epithelium, acts as a potent regulator of actin polymerization and the cytoskeletal network. In this study, we identified the specific role of endometrial PFN1 during embryo implantation.Methods: Morphological alterations depending on the status of PFN1 expression were assessed in PFN1-depleted or control cells grown on Matrigel-coated cover glass. Day-5 mouse embryos were cocultured with Ishikawa cells. Comparisons of the rates of F-actin formation and embryo attachment were performed by measuring the stability of the attached embryo onto PFN1-depleted or control cells.Results: Depletion of PFN1 in endometrial epithelial cells induced a significant reduction in cell-cell adhesion displaying less formation of colonies and a more circular cell shape. Mouse embryos co-cultured with PFN1-depleted cells failed to form actin cytoskeletal networks, whereas more F-actin formation in the direction of surrounding PFN1-intact endometrial epithelial cells was detected. Furthermore, significantly lower embryo attachment stability was observed in PFN1-depleted cells than in control cells. This may have been due to reduced endometrial receptivity caused by impaired actin cytoskeletal networks associated with PFN1 deficiency.Conclusion: These observations definitively demonstrate an important role of PFN1 in mediating cell-cell adhesion during the initial stage of embryo implantation and suggest a potential therapeutic target or novel biomarker for patients suffering from implantation failure.
- 1 June 2020
- Published by The Korean Society for Reproductive Medicine in Clinical and Experimental Reproductive Medicine
- Vol. 47 (2) , 114-121
Open AccessEndometrial profilin 1: a key player in embryo-endometrial crosstalk
Objective: Despite extensive research on implantation failure, little is known about the molecular mechanisms underlying the crosstalk between the embryo and the maternal endometrium, which is critical for successful pregnancy. Profilin 1 (PFN1), which is expressed both in the embryo and in the endometrial epithelium, acts as a potent regulator of actin polymerization and the cytoskeletal network. In this study, we identified the specific role of endometrial PFN1 during embryo implantation.Methods: Morphological alterations depending on the status of PFN1 expression were assessed in PFN1-depleted or control cells grown on Matrigel-coated cover glass. Day-5 mouse embryos were cocultured with Ishikawa cells. Comparisons of the rates of F-actin formation and embryo attachment were performed by measuring the stability of the attached embryo onto PFN1-depleted or control cells.Results: Depletion of PFN1 in endometrial epithelial cells induced a significant reduction in cell-cell adhesion displaying less formation of colonies and a more circular cell shape. Mouse embryos co-cultured with PFN1-depleted cells failed to form actin cytoskeletal networks, whereas more F-actin formation in the direction of surrounding PFN1-intact endometrial epithelial cells was detected. Furthermore, significantly lower embryo attachment stability was observed in PFN1-depleted cells than in control cells. This may have been due to reduced endometrial receptivity caused by impaired actin cytoskeletal networks associated with PFN1 deficiency.Conclusion: These observations definitively demonstrate an important role of PFN1 in mediating cell-cell adhesion during the initial stage of embryo implantation and suggest a potential therapeutic target or novel biomarker for patients suffering from implantation failure.
- Open Access
- 1 June 2020
- Published by The Korean Society for Reproductive Medicine in Clinical and Experimental Reproductive Medicine
- Vol. 47 (2) , 108-113
Eupatilin treatment inhibits transforming growth factor beta-induced endometrial fibrosis in vitro
Objective: Endometrial fibrosis, the primary pathological feature of intrauterine adhesion, may lead to disruption of endometrial tissue structure, menstrual abnormalities, infertility, and recurrent pregnancy loss. At present, no ideal therapeutic strategy exists for this fibrotic disease. Eupatilin, a major pharmacologically active flavone from Artemisia, has been previously reported to act as a potent inducer of dedifferentiation of fibrotic tissue in the liver and lung. However, the effects of eupatilin on endometrial fibrosis have not yet been investigated. In this study, we present the first report on the impact of eupatilin treatment on transforming growth factor beta (TGF-β)-induced endometrial fibrosis.Methods: The efficacy of eupatilin on TGF-β–induced endometrial fibrosis was assessed by examining changes in morphology and the expression levels of fibrosis markers using immunofluorescence staining and quantitative real-time reverse-transcription polymerase chain reaction.Results: Eupatilin treatment significantly reduced the fibrotic activity of TGF-β–induced endometrial fibrosis in Ishikawa cells, which displayed more circular shapes and formed more colonies. Additionally, the effects of eupatilin on fibrotic markers including alpha-smooth muscle actin, hypoxia-inducible factor 1 alpha, collagen type I alpha 1 chain, and matrix metalloproteinase-2, were evaluated in TGF-β–induced endometrial fibrosis. The expression of these markers was highly upregulated by TGF-β pretreatment and recovered to the levels of control cells in response to eupatilin treatment.Conclusion: Our findings suggest that suppression of TGF-β–induced signaling by eupatilin might be an effective therapeutic strategy for the treatment of endometrial fibrosis.
- 1 June 2020
- Published by The Korean Society for Reproductive Medicine in Clinical and Experimental Reproductive Medicine
- Vol. 47 (2) , 108-113
Open AccessEupatilin treatment inhibits transforming growth factor beta-induced endometrial fibrosis in vitro
Objective: Endometrial fibrosis, the primary pathological feature of intrauterine adhesion, may lead to disruption of endometrial tissue structure, menstrual abnormalities, infertility, and recurrent pregnancy loss. At present, no ideal therapeutic strategy exists for this fibrotic disease. Eupatilin, a major pharmacologically active flavone from Artemisia, has been previously reported to act as a potent inducer of dedifferentiation of fibrotic tissue in the liver and lung. However, the effects of eupatilin on endometrial fibrosis have not yet been investigated. In this study, we present the first report on the impact of eupatilin treatment on transforming growth factor beta (TGF-β)-induced endometrial fibrosis.Methods: The efficacy of eupatilin on TGF-β–induced endometrial fibrosis was assessed by examining changes in morphology and the expression levels of fibrosis markers using immunofluorescence staining and quantitative real-time reverse-transcription polymerase chain reaction.Results: Eupatilin treatment significantly reduced the fibrotic activity of TGF-β–induced endometrial fibrosis in Ishikawa cells, which displayed more circular shapes and formed more colonies. Additionally, the effects of eupatilin on fibrotic markers including alpha-smooth muscle actin, hypoxia-inducible factor 1 alpha, collagen type I alpha 1 chain, and matrix metalloproteinase-2, were evaluated in TGF-β–induced endometrial fibrosis. The expression of these markers was highly upregulated by TGF-β pretreatment and recovered to the levels of control cells in response to eupatilin treatment.Conclusion: Our findings suggest that suppression of TGF-β–induced signaling by eupatilin might be an effective therapeutic strategy for the treatment of endometrial fibrosis.